Company gets 10-year exclusivity to distribute cGMP insulin replacement for industrial processes.
Novozymes Biopharma and Sigma-Aldrich’s SAFC division announced a 10-year extension to their agreement giving the latter exclusive marketing and distribution rights to Novozyme’s Long® R3IGF-1 (Long R3) growth factor. It is used as a cGMP alternative to recombinant insulin for industrial cell culture applications.
The product is designed to boost the productivity and performance of cell culture processes. It replaces the requirement for insulin and specifically binds to type 1 IGF receptors to stimulate cell growth and support survival in serum-free media.
“It is exciting to see how the unique attributes of Long R3 meet key development and manufacturing challenges as cell culture processes continue to become more sophisticated,” comments Michael D. James, SAFC’s marketing manager. “This exclusive 10-year agreement is expected to enhance SAFC’s market-leading position as a critical raw material supplier into the biologic and vaccines market.”
